Cancer vaccine-MUC 1

Drug Profile

Cancer vaccine-MUC 1

Alternative Names: Anti-MUC1 Sp therapeutic vaccine - Vaxil Biotherapeutics; Anti-MUC1 therapeutic cancer vaccine (ImMucin) - Vaxil BioTherapeutics; Cancer vaccine MUC-1; ImMucin; MUC-1; VXL-100

Latest Information Update: 08 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vaxil BioTherapeutics
  • Developer Hadassah Medical School; Vaxil BioTherapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Breast cancer; Multiple myeloma
  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 03 May 2018 Vaxil has patent protection for cancer vaccine-MUC 1 in India, Israel, European Union, Canada and USA
  • 30 Jan 2018 Vaxil plans a phase II trial for Solid tumours
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Israel (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top